Celcuity

Celcuity is a clinical-stage biotechnology company dedicated to extending the lives of cancer patients. They specialize in developing first-in-class therapies and companion diagnostics for various cancers. Celcuity's unique approach focuses on unraveling complex oncogenic activity that traditional molecular tests often miss. Their proprietary CELsignia platform analyzes live tumor cells, providing a dynamic view of pathway signaling and identifying previously undetectable cancer drivers.

Celcuity's lead drug candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. This drug is currently being developed for advanced breast cancer and metastatic castration resistant prostate cancer. Celcuity is conducting multiple clinical trials to assess the safety and efficacy of gedatolisib, aiming to provide new treatment options for patients with unmet medical needs. Their focus on both therapeutic development and companion diagnostics allows for more personalized and effective cancer treatment.

Celcuity is a clinical-stage biotechnology company focused on extending the lives of cancer patients. They develop potential first-in-class therapies and companion diagnostics by leveraging their proprietary CELsignia platform, which analyzes complex oncogenic activity in live tumor cells, allowing them to discover previously undetectable cancer drivers and identify patients who may benefit from targeted therapies.

Celcuity cultivates a collaborative and innovative environment where a team of experts from diverse scientific backgrounds work together to develop groundbreaking treatments for cancer. The company emphasizes a patient-centric approach, prioritizing the development of therapies that address unmet needs in the fight against cancer. Celcuity fosters a culture of continuous learning and growth, empowering employees to contribute their unique skills and insights towards achieving a shared mission of extending the lives of cancer patients.

Celcuity is committed to fostering a diverse, equitable, and inclusive workplace. They believe that a diverse workforce strengthens their ability to develop innovative solutions for cancer patients. Their efforts include creating a welcoming environment for all employees, actively recruiting from diverse talent pools, and promoting equitable opportunities for career growth and development. The company is dedicated to ensuring that all voices are heard and valued, contributing to a thriving and impactful company culture.